Artiva Biotherapeutics to Showcase AlloNK Cost-Effectiveness and Durability Data at 2026 Tandem Meetings
Event summary
- Artiva Biotherapeutics will present two posters at the 2026 Tandem Meetings on February 5, 2026.
- One poster highlights the cost-effectiveness of AlloNK in community rheumatology practice compared to CAR-T treatments.
- The second poster presents data on the continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL).
- AlloNK is an off-the-shelf, non-genetically modified NK cell therapy candidate.
The big picture
Artiva Biotherapeutics is positioning AlloNK as a cost-effective and durable alternative to CAR-T treatments, addressing key pain points in both autoimmune diseases and cancer therapy. The presentations at the 2026 Tandem Meetings aim to reinforce AlloNK's strategic advantage in accessibility and long-term efficacy, potentially reshaping the competitive landscape in cell therapy.
What we're watching
- Cost Efficiency
- How the cost-effectiveness data of AlloNK in rheumatology practice will impact its adoption in community settings.
- Clinical Durability
- Whether the continued durability of AlloNK in NHL will support its long-term viability in the market.
- Market Positioning
- The pace at which Artiva can differentiate AlloNK from existing CAR-T treatments based on the presented data.
Related topics